Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
Jeffrey L. Lennox(Emory University), Susan L. Koletar(Johns Hopkins University), Randi Y. Leavitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lumine H. Na(Brigham and Women's Hospital), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), David W. Haas(Meharry Medical College), Catherine Godfrey(United States Department of State), Daniel Seekins(Brigham and Women's Hospital), Manish Sagar(Evidence (Italy)), Rachel M. Presti(Johns Hopkins University), Raphael J. Landovitz(APLA Health), Susan E. Cohn(Brigham and Women's Hospital), James F. Rooney(Gilead Sciences (United States)), Daniel R. Kuritzkes(Brigham and Women's Hospital), Bryan Baugh(Brigham and Women's Hospital), Francesca Aweeka(University of California, San Francisco), Todd T. Brown(Johns Hopkins University), Ighovwerha Ofotokun(Emory University), Constance A. Benson(University of Colorado Health), Judith S. Currier(University of California, Los Angeles), Grace A. McComsey(University Hospitals of Cleveland), Kristine B. Patterson(University of North Carolina at Chapel Hill)
Cited by 260
Related Papers
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981